The biotransformation of acetophenetidin in the alloxan-diabetic rabbit

Sex differences in salicylic acid metabolism in streptozotocin induced diabetes in rats

The metabolism of salicylic acid was studied in male and female streptozotocin-induced diabetic Wistar rats. Results obtained showed that in both sexes there was a significant increase in urinary excretion of salicyluric acid in diabetic rats when compared to controls (P less than or equal to 0.001). Within the diabetic groups, there was a significant increase in the urinary excretion of salicyluric acid in the female in comparison to the male rats (P less than or equal to 0.01). A statistically significant increase was observed in urinary excretion of salicyl-glucuronic acid in diabetic female compared to control female rats (P less than or equal to 0.01) while comparison of diabetic male to control male showed a significant decrease in urinary excretion of salicyl-glucuronic acid (P less than or equal to 0.01). Comparison of the diabetic female and male groups showed a high statistically significant difference in urinary excretion of salicyl-glucuronic acid. The diabetic ration, ie diabetic/control was significantly higher in female than in male rats with respect to salicyl-glucuronic acid (P less than or equal to 0.001) and total urinary excretion (P less than or equal to 0.01). The diabetic ratio may likely reflect the true significance of the roles played by the two metabolic pathways. The results suggest sex differences in the metabolism of salicylic acid; this may also be the case in other disease states.

Effect of diabetes mellitus on salivary paracetamol elimination

1. Salivary elimination of paracetamol was studied in nine type I and ten type II diabetics. Ten healthy volunteers served as a control group. 2. A significant increase in the elimination half-life (t1/2) and apparent volume of distribution was observed in type I diabetics compared with controls. Clearance rate (CL) was not significantly altered. 3. In type II diabetics paracetamol elimination t1/2 was significantly increased with a corresponding decrease in CL. Apparent volume of distribution of the drug was not significantly different. 4. Paracetamol elimination t1/2 had significant correlation with fasting blood sugar values.

Effects of experimental diabetes on aminopyrine metabolism in rats

1. The metabolism of aminopyrine has been investigated in normal, alloxan- and streptozotocin (STZ)-diabetic rats. The drug was administered i.p. and the serum concentrations of the unchanged aminopyrine and its main metabolites were measured using h.p.l.c. 2. Aminopyrine was metabolized at a slower rate in both diabetic rats, as judged from higher serum levels of the unchanged drug. Pharmacokinetic studies of aminopyrine in diabetic rats also showed a decrease in serum clearance of the drug and an increase in its serum half-life. 3. The serum concentrations of the metabolites 4-monomethylaminoantipyrine, 4-acetylaminoantipyrine and 4-formylaminoantipyrine decreased in diabetic rats. In contrast, serum levels of 3-hydroxymethyl-2-methyl-4-dimethylamino-1-phenyl-3-pyrazolin-5-on e increased over control values. Serum concentrations of 4-aminoantipyrine remained unaltered by the induction of diabetes. 4. The magnitudes of changes in serum levels of these metabolites were larger in alloxan-diabetes than in STZ-diabetes. 5. Additional support for changed metabolism of aminopyrine was obtained from the investigation of microsomal preparations from diabetic and normal rats. 6. These findings indicate that it is important to use intact animals for evaluation of the metabolism of drugs in pathological states.

Diabetes alters drug metabolism--in vivo studies in a streptozotozin-diabetic rat model

The influence of experimental streptozotozin-induced diabetes on hepatic drug metabolism in vivo has been studied in rats, using 14CO2-exhalation after 14C-aminopyrine injection. Male diabetic rats showed a decreased (-18%), females an increased (+19%) 14CO2-exhalation compared to controls, indicating altered hepatic drug metabolism due to diabetes.

The metabolism and disposition of [2-14C]diazepam in the streptozotocin-diabetic rat

The oral administration of [2-14 C]diazepam to streptozotocin (STZ)-diabetic rats resulted in decreased faecal and biliary levels of metabolites with a concomitant rise in urinary radioactivity when compared to control values. This situation was reversible upon insulin treatment. The increased urinary metabolite excretion could not be ascribed to the diuresis observed in STZ-diabetic rats. No alteration in the phase I or II routes of [14C]diazepam metabolism in diabetic animals was observed either in vivo or in vitro. Following i.v. administration of [2-14C]diazepam, blood 14C levels in diabetic rats were elevated above those observed in normal animals.